PCM
RVLP

Prelude Capital Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Prelude Capital Management’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,317
Closed -$51K – 2172
2019
Q4 		$51K Buy
+7,317
New +$39K ﹤0.01% 1334

Other funds holding RVLP

SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prelude Capital Management's RVLP Position: Q1 2020 in Review

Prelude Capital Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q1 2020, closing a stake of 7,317 shares — an estimated $51K sold.

Prelude Capital Management first reported a position in RVLP in Q4 2019 and held it in 1 quarter. The position peaked at $51K in Q4 2019. 62 funds tracked by Wall St. Rank hold RVLP as of Q1 2020.

  • Prelude Capital Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 7,317 RVL Pharmaceuticals plc Ordinary Shares shares in Q1 2020, an estimated $51K.
  • Prelude Capital Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2019 and held it in 1 quarter.
  • Prelude Capital Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $51K in Q4 2019.
  • 62 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.